<DOC>
	<DOCNO>NCT00669318</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pentostatin , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , alemtuzumab rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving pentostatin together alemtuzumab rituximab may kill cancer cell . PURPOSE : This phase II trial study well give pentostatin together alemtuzumab rituximab work treat patient relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma .</brief_summary>
	<brief_title>Pentostatin , Alemtuzumab , Rituximab Treating Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess rate complete overall response patient relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma treat pentostatin , alemtuzumab , low-dose rituximab . - To monitor assess toxicity treatment regimen . Secondary - To determine overall progression-free survival , duration response , time next treatment . - To assess correlation individual prognostic marker ( 17p- , 11q- , unmutated VH gene , VH3-21 , ZAP-70+ , CD38+ , CD49d , β2 microglobulin , miRNA profile , angiogenesis status , karyotypes CpG stimulate cell ) clinical outcome . OUTLINE : This multicenter study . - Course 1 : Patients receive pentostatin IV day 8 22 ; alemtuzumab subcutaneously ( SC ) day 3-5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 ; rituximab IV day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 ; sargramostim ( GM-CSF ) SC day 10-14 24-28 . Patients proceed course 2 . - Courses 2 3 : Patients receive pentostatin IV day 1 15 ; alemtuzumab SC rituximab IV day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 ; GM-CSF SC day 3-7 17-21 . After completion course 2 , patient complete response proceed observation . Patients partial response stable disease receive another course therapy ( course 3 ) . Treatment continue absence disease progression unacceptable toxicity . Blood collect day 1 , 3 , 8 , 10 course 1 monoclonal antibody study . Samples analyze serum concentration alemtuzumab rituximab ELISA PCR ; CH50 assay ; complement activation cytokine level ELISA ; NK cell activation ; NK cell phenotype immunofluorescent stain flow cytometry . After completion study treatment , patient follow monthly 6 month , every 3 month 6 month , every 6-12 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) meeting follow criterion : Minimum threshold peripheral blood lymphocyte count 5 x 10^9/L ( CLL variant ) OR adenopathy &gt; 1 cm palpable splenomegaly ( SLL variant ) Immunophenotypic demonstration population B lymphocytes ( defined CD19+ ) monoclonal ( light chain exclusion ) AND ≥ 3 follow characteristic : CD5+ CD23+ Dim surface light chain expression Dim surface CD20 expression FISH analysis negative IGH/CCND1 and/or immunostaining negative cyclin D1 expression Must progressive disease indicate follow characteristic ( base standard criterion treatment ) : Symptomatic CLL characterize follow : Weight loss &gt; 10 % within past 6 month Extreme fatigue Fevers &gt; 38.5° C ( due infection ) Drenching night sweat without evidence infection Evidence progressive bone marrow failure hemoglobin &lt; 11 g/dL platelet count &lt; 100 x 10^9/L Massive progressive splenomegaly ( &gt; 6 cm leave costal margin ) Massive ( &gt; 10 cm ) rapidly progressive lymphadenopathy PATIENT CHARACTERISTICS : ECOG performance status 03 Creatinine ≤ 2 time upper limit normal ( ULN ) Total bilirubin ≤ 3.0 time ULN OR direct bilirubin ≤ 1.5 time ULN AST ≤ 3.0 time ULN ( unless due hemolysis CLL ) Willing provide mandatory blood sample research study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No active primary malignancy require treatment limit survival ≤ 2 year No active autoimmune hemolytic anemia , immune thrombocytopenia , pure red blood cell aplasia No New York Heart Association class III IV heart disease No myocardial infarction within past month No uncontrolled infection No HIV infection AIDS No active hepatitis B infection ( i.e. , HBsAg HBeAg positivity ) hepatitis C infection serology No comorbid condition PRIOR CONCURRENT THERAPY : No 3 prior treatment regimen CLL include purine analogue drug ( e.g. , fludarabine , pentostatin , cladribine ) OR previously untreated CLL patient highrisk disease due 17p13 deletion FISH analysis More 4 week since prior major surgery More 2 month since prior alemtuzumab Prior corticosteroid allow No concurrent continuous systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>